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Abstract
Background: Previous studies demonstrated that the vascular endothelial growth factor (VEGF) was being implicated in 
the airways inﬂ  ammation and remodeling process in patients with asthma.
Aims: We explored the relationship of three polymorphisms in the VEGF gene with asthma in both case control and family 
studies.
Methods: We Genotyped a total of 210 children with asthma, 224 unrelated controls and 160 parents for the 
+936 C   T (rs3025039), −634 G   C (rs2010963) and −2549 –2567 del 18 of the VEGF promoter region. The Mutations 
were identiﬁ  ed with polymerase chain reaction followed by restriction fragment length polymorphism (RFLP) analysis for 
the +936 C   T, and −634 G   C polymorphisms.
Results: Of the three polymorphisms studied, a borderline association with asthma was found for the G allele in the −634 
G   C polymorphism (p = 0.059). No Statistically signiﬁ  cant differences were observed for both +936 C   T, and −2549 
–2567 del 18 polymorphisms between asthmatic patients and controls, considering either allelic or genotypic frequencies. 
The distribution of genotypes according to the severity status revealed a signiﬁ  cant differences for the +936 C   T, and 
−2549 –2567 del 18 polymorphisms. In addition, association was found with the haplotypes inferred by the three polymor-
phisms and asthma susceptibility.
Conclusion: We suggest that VEGF Gene polymorphisms can be implicated in asthma.
Keywords: VEGF, polymorphisms, asthma
Introduction
Vascular endothelial growth factor (VEGF) is a major angiogenic factor and is a prime regulator of 
endothelial cell proliferation. It plays a crucial role in physiological vasculogenesis and vascular perme-
ability (Ferrara, 1992 and Yancopoulos, 2000) The VEGF gene expression is regulated by a variety of 
hormones, growth factors, lipopolysaccharide (LPS) (Watson, 2000) hypoxia (Neufeld, 1999), and cyto-
kines (Ferrara, 1999), including, Platelet Derived Growth Factor (PDGF), Epidermal Growth Factor 
(EGF), Transforming Growth Factor β (TGF-b), Interleukine 1 (IL-1) and Interleukine 6 (IL-6) (Ferrara, 
2003), suggesting that several other angiogenic factors may act by regulating VEGF expression (Klags-
brun, 1996). Increased VEGF expression resulting in inappropriate VEGF-induced angiogenesis is 
implicated in a number of disease pathologies. It is also widely expressed within many different highly 
vascularized organs, including the lung (Maniscalco, 1997). Compelling evidence suggests that mucosal 
neovascularisation occurs in chronic asthma (Li, 1997 and Salvato, 2001) and the VEGF level was 
increased in the airways of subjects with both acute (Hoshino, 2001) and stable (Lee, 2001) asthma. 
Studies have implicated growth factors including vascular VEGF and ﬁ  broblast growth factor 2 (FGF2) 
derived from eosinophils, macrophages and smooth muscle cells in its causation (Hoshino, 2001). Inverse 
correlation of mucosal vascularity with airway calibre (Salvato, 2001) suggests that neovascularisation 90
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may contribute to airways obstruction. It has been 
reported that both the number and percentage of 
vessels in bronchial mucosa taken from subjects 
with even mild asthma were higher than those in 
control subjects (Li, 1997; Kuwano, 1993; Chetta, 
2005). There is increasing evidence to support a 
key role for VEGF, as a mediator of structural 
changes in the airway wall of asthmatics. Further 
the VEGF was produced by epithelial cells and 
preferentially by Th2 versus Th1 cells. In this set-
ting, it had a critical role in Th2 inﬂ  ammation, 
cytokine production and physiologic dysregulation 
of atopic disease (Lee, 2004).
The human VEGF gene is localized in chromo-
some 6p21.3 (Lutty, 1996) and comprises a 14-kb 
coding region organized in eight exons, separated 
by seven introns (Vincenti, 1996). This region of 
the genome (6p21) contains the major histocompat-
ibility complex (MHC) and shows the strongest 
evidence for linkage to the asthma phenotype in 
most studies (wjst, 1999). The VEGF gene includes 
at least three polymorphisms that are relatively 
common and may inﬂ  uence VEGF expression. Two 
of these polymorphisms are located in the promoter 
region at −2549 –2567 del 18 and −634 G   C 
(rs2010963), relative to the translation start site, 
and have been associated with increased VEGF 
expression (Lambrechts, 2003 and Shahbazi, 2002) 
The third polymorphism located in the 3’ untrans-
lated region (+936 C   T; rs3025039) is associated 
with substantially increased serum VEGF levels 
(Renner, 2000 and Krippl, 2003). Given that no 
data was shown to approve or to deny the implica-
tion of these polymorphisms with asthma disease, 
we further investigated the role of these polymor-
phisms in Tunisian asthmatic children.
Material and Methods
Subjects
Controls
The control group consisted of 224 children present-
ing to the emergency department of Tunis Children 
Hospital with other than respiratory or atopic com-
plaints. To qualify as a control subjects, there should 
be no history of respiratory disease or asthma and 
no ﬁ  rst degree relative with a history of asthma. All 
those controls did not suffer from any chronic disease 
and did not have any allergic disease (gave negative 
skin prick results, had normal total IgE level  200 
UI/ml). Patients and controls belonged to the same 
ethnic group: African white Caucasian.
Patients
A total of 210 children (aged from 5 to 16 years, mean 
age 11.5) were enrolled in this study. The diagnosis 
and classiﬁ  cation of the clinical severity of asthma 
was made according to the GINA guidelines.
This group of asthmatic children consisted of 5 
subjects with intermittent asthma, 135 with mild 
persistent asthma, 60 with moderate persistent 
asthma, and 10 with severe persistent asthma. 
Atopic status was deﬁ  ned by a positive skin test 
reaction characterized by a wheal of 3mm in diam-
eter, to a panel of common allergens in the presence 
of a positive histamine control and a negative 
uncoated control, and by measurement of total IgE 
level: positive values were taken as  200 IU/ml. 
(BECKMAN.Access Immunoassay system.FR).
Among the 210 asthmatic children there were 
139 atopics and 71 non atopics who had negative 
skin test responses to common allergens (skin prick 
tests were performed by specially trained nurses 
with a panel of common allergens). In our study 
asthma was frequently associated with a heteroge-
neous group of clinical disorders including rhinitis, 
sinusitis and dermatitis. The clinical proﬁ  les are 
shown in table 1.
Families
Among the 210 asthmatic children, forty of them 
and their respective parents were also studied for 
linkage analyses.
All families were African white Caucasian and 
comprised the two parents and an affected child. 
Information on the prevalence of physician diag-
nosis of asthma in each family was ascertained by 
a questionnaire completed separately for each fam-
ily member by the parents.
The study was approved by our National Ethics 
Committee and was conducted in accordance with 
the guidelines in the declaration of Helsinki. 
Informed consent was obtained from all parents of 
asthmatics and controls participating in this study.
Genotyping of Polymorphisms 
Within the VEGF Gene
All asthmatics, their parents and controls were 
genotyped by polymerase chain reaction—based 91
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restriction fragment length polymorphism. For 
+936 C   T (rs3025039) and −634 G   C 
(rs2010963) mutations and a simple polymerase 
chain reaction for 2549 –2567 del 18 of the VEGF 
promoter region.
The Total volume of the PCR was 25 µl contain-
ing 100 ng of genomic DNA, 1x PCR- Buffer 
(Qiagen, Hilden, Germany), 0.5mM Of a dNTP- 
Mix (Fermentas), 0.5 Units of Taq DNA Poly-
merase (Fermentas) And 3 pmol of each primer 
(Biomers, Belgium). The Final MgCl2 Concentra-
tions are 2, 3 and 4 respectively for the three poly-
morphisms. The primer used for +936 C   T are 
F: 5’- aaggaagaggagactctgcgcagagc-3’ R: 5’-taaat-
gtatgtatgtgggtgggtgtgtctacag-3’, for −634 G   C 
F: 5’- atttatttttgcttgccatt-3’ R: 5’-gtctgtctgtctgtcc-
gtca-3’, and for 2549 –2567 del 18 are F: 5’-cctg-
gagcgttttggttaaa-3’ R: 5’-atataggaagcagcttggaa-3’. 
The PCR Comprised an initial denaturation step ( 
95°C for 15 min.), 35 Cycles ( 95°C for 30 s, primer 
annealing temperature (66°C for +936 C   T, 59°C 
for -634 G   C and 54°C for 2549 –2567 del 18 
for 30 s), 72°C for 30 s and a ﬁ  nal extension step 
( 72°C For 10 min.). The Volume of the restriction 
assays was 25 µl containing 10 µl of the PCR 
product, the appropriate Buffer, and 5U of each 
restriction enzyme Hin1II and FaqI for +936 C   T 
and −634 G   C polymorphisms respectively 
(Fermentas). For the +936 C   T the assay thus 
yields two bands: 122 and 86 bp for TT genotype, 
three bands for CT genotype: 208, 122, and 86 bp 
and one 208 bp band for CC. For the −634 G   C 
the assay thus yields two bands: 193 and 111 bp 
for GG genotype, three bands for GC genotype: 
193, 111, and 304 bp and one 304 bp band for CC 
genotype. For the 2549 –2567 del 18 the Fragment 
Sizes were 234 bp when the insertion of 18(bp) is 
present and 216 bp when the deletion of 18 (bp) is 
present.
Statistical Analysis
Differences in alleles and genotypes frequencies 
between patients and healthy controls were com-
pared using the standard Chi squared test (Epistat 
statistical package Epi Info version 6). When the 
expected cell number was less than 5, Fisher’s 
exact test was used. The strength of a gene asso-
ciation is indicated by the odds ratio (OR). The 
odds ratio and the 95% conﬁ  dence intervals (CI) 
were calculated whenever applicable. Haplotypes 
analyses were determined based on a Bayesian 
algorithm using the phase program.
For the linkage analyses in family study, the 
TDT was used to test for transmission of alleles at 
a particular locus from heterozygous parents to 
their affected offspring (Spielman, 1993).The 
proportion of alleles transmitted from both mother 
and father was tested against a null hypothesis of 
50% transmission by χ2 analysis. Probability 
values of 0.05 or less were regarded as statistically 
signiﬁ  cant.
Results
The association between asthma and VEGF poly-
morphisms (+936 C   T, −634 G   C and −2549 
Table 1. The clinical characteristics of our study samples.
   Controls  Asthmatics
 Number  of  subjects  224  210
  Age [mean(Standard deviation)]  9.5 (5–16)  11.5 (5–16)
  Mean age at the onset of asthma    4.6
  Sex ratio (girl / boy)  0.88  0.64
 Asthma  in  families 0  40%
  FEV 1*%, predicted mild asthma    86
  FEV 1%, predicted moderate asthma    70
  FEV 1%, predicted severe asthma    56
  Total IgE (IU/ml) atopic    640.04
  Total IgE (IU/ml) non atopic  62.30  58.8
Phenotypes associated  rhinitis  0  14%
 sinusitis  0  11%
 dermatitis  0  3%
 RGO**  0  10%
*FEV1%, predicted: forced expiratory volume in 1s.
**RGO: gastro-oesophageal reﬂ  ux.92
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–2567 del 18) was investigated by determining the 
occurrence of each genotype and alleles in asth-
matic and control children. No signiﬁ  cant differ-
ence was detected between the patient and control 
groups in genotype distribution of any of the poly-
morphisms studied (p = 0.15) (p = 0.059) (p = 0.56) 
respectively for +936 C   T, −634 G   C, and for 
−2549 –2567 del 18 (Table 2). The results showed 
that alleles of neither the +936 C   T, nor −2549 
–2567 del 18 were found to be associated with 
asthma. A slight borderline association was found 
with allele distribution of the −634 G   C poly-
morphisms (p = 0.059).
We also estimated haplotypes for the +936 C   
T, −634 G   C and −2549 −2567 del 18 Haplotypes 
analyses on these polymorphisms revealed func-
tionally distinct haplotypes associated with asthma 
(p   10
-3 ) (Table 3). There are total of seven com-
mon haplotypes among both cases and controls. 
The distribution of different haplotypes was not 
similar between asthmatic and control children. 
The Most common haplotypes were: the −634C 
/+936C /−2549D, with the frequencies of 32.14% 
and 33.25% and −634G /+936C /−2549I with the 
frequencies of 32.38% and 36.38% in respectively 
cases and controls. Two Haplotypes −634G /+936T 
/−2549D (p = 0.0004) and −634C /+936T /−2549D 
(p = 0.014) were associated with asthma including 
the last one which present signiﬁ  cantly higher risk 
with an OR (95% CI) = 1.53 (1.07−2.18).
After applying the appropriate statistical analy-
ses for each genetic variant, we did not observe 
any statistically signiﬁ  cant deviation of the +936 
C   T, −634 G   C and −2549 –2567 del 18 vari-
ants between atopic asthmatics and non atopic one 
(Table 4). The distribution of haplotype frequencies 
did not show any statistically signiﬁ  cant differ-
ences between atopic and non atopic groups (data 
not shown).
A statistically signiﬁ  cant difference was dem-
onstrated for genotype distribution of the VEGF 
polymorphisms +936 C   T (p = 0.0001) and for 
−2549 −2567 del 18 (p = 0.02), when the intermit-
tent/mild and moderate/severe asthmatics were 
compared (Table 5).
Family study
Implicitly, we also assume that disease-susceptibility 
alleles are preferentially transmitted from parents 
to the affected offspring and that this effect can be 
captured by the transmission/ disequilibrium test 
(TDT). We tested eighty families of asthmatic 
children for a possible association between asthma 
and VEGF polymorphisms. Only 65, 68 and 71 
families respectively for the -634 G   C, +936 
C   T and 2549 –2567 del 18 polymorphisms, on 
which we can apply for the TDT (Table 6). TDT 
analysis showed transmission of C, C, and D allele 
of respectively −634 G   C, +936 C   T and 
Table 2. Frequency of alleles and distribution of genotypes of VEGF polymorphisms in asthmatics and controls 
subjects.
SNP Genotypes Alleles
Asthmatics 
n (%)
Controls
n (%)
χ
2 P 
value*
Asthmatics
n (%)
Controls
n (%)
χ
2 P
value**
OR
(95% CI)
+936 CC 110(52.4) 132 (58.9) 1.9 0.3 2.0 0.15 0.80
CT 80 (38.1) 75 (33.5) C 300 (71.4) 339 (75.7) (0.59–1.10)
TT 20 (9.5) 17 (7.6) T 120 (28.6) 109 (24.3)
−634 GG 37 (17.6) 52 (23.2) 3.8 0.14 3.5 0.059 0.77
GC 111 (52.9) 122 (54.5) G 185 (44) 226 (50.4) (0.59–1.02)
CC 62 (29.5) 50 (22.3) C 235 (56) 222 (49.6)
−2549 −2567 
del 18
30 (14.3) 24 (10.7) 5.3 0.07 0.3 0.56 1.08
(I/I) (0.82–1.44)
(I/D) 96 (45.7) 127 (56.7) I 156 (37.1) 175 (39.1)
(D/D) 84 (40) 73 (32.6) D 264 (62.9) 273 (60.9)93
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2549 –2567 del 18 polymorphisms to offspring 
with asthma occurred more frequently than G, T 
and I allele but not signiﬁ  cant (p = 0.17) (p = 0.22) 
(p = 0.09).
Discussion
Asthma is a chronic inﬂ  ammatory disease charac-
terized by some common changes in asthmatic 
airway walls including growth and proliferation of 
new vessels (2002). Increased VEGF levels in 
induced sputum, (Asai, 2003; Asai, 2002; 
Kanazawa, 2002) bronchoalveolar lavage ﬂ  uid, 
(Feltis, 2006) and VEGF-positive cells in bronchial 
biopsies (Hoshino, 2001) have been found in 
patients with asthma compared to healthy controls. 
The increased vascularity of bronchial mucosa in 
asthmatic subjects has been related to increased 
numbers of VEGF-positive cells, suggesting a 
pathogenic role for VEGF in the pathology of the 
asthmatic airway (Hoshino, 2001). In addition, 
VEGF has been related to increased basement 
membrane thickness in biopsies from asthmatic 
patients, suggesting a possible role of VEGF in 
airway remodeling (Chetta, 2005).Given the 
important role of VEGF in asthma we performed 
a genetic study concerning VEGF in asthma.
The present study is the ﬁ  rst to be conducted on 
asthmatic children, there are no studies of asthma 
and VEGF variants have been performed. We tested 
for an association between markers in VEGF gene 
with asthma. Given the important role of VEGF in 
the remodeling process in asthma, we looked for a 
possible difference in the allele and genotype fre-
quencies of three polymorphisms (+936 C   T, −634 
G   C and −2549 –2567 del 18 asthmatic and 
control children. For −2549 –2567 del 18 of the 
VEGF promoter region, we found no evidence of 
association between this polymorphism and asthma, 
which was supposed to have functional relevance 
in VEGF promoter activity. When we compared the 
distribution of genotypes among the group of asth-
matics according to the severity status we conclude 
that two of these polymorphisms +936 C   T, and 
−2549 –2567 del 18 are associated with the severity 
status. Although the speciﬁ  c role of this polymor-
phism in the VEGF gene has not yet been elucidated, 
it appears that the D allele increase VEGF expres-
sion, as assessed by the increased VEGF activity 
of transcription 1.95 fold compared to the I allele 
(Yang, 2003). In addition to this promoter region 
polymorphism, the C allele of a common polymor-
phism located in the 3’ untranslated region (+936 
C   T) is known to be associated with substantially 
Table 3. Haplotypes frequency of VEGF gene polymorphisms in asthmatics and controls children.
Haplotypes  −634  936  18  Asthmatics n (%)  Controls n (%)  χ
2  P value  OR (95% CI)
ht 1  G  C  I  136 (32.38)  163 (36.38)  1.54  0.2 
ht 2  G  T  I  15 (3.57)  11 (2.45)    NS 
ht 3  G  C  D  29 (6.9)  27 (6.02)    NS 
ht 4  G  T  D  5 (1.2)  25 (5.58)  12.52  0.0004  0.20 (0.07–0.57)
ht 5  C  T  I  5 (1.2)  1 (0.22)    NS 
ht 6  C  C  D  135 (32.14)  149 (33.25)    NS 
ht 7  C  T  D  95 (22.61)  72 (16.07)  5.98  0.014  1.53 (1.07–2.18)
Haplotypes combinations
1/1 GG  CC  II  20  23    10
−3 
1/2 GG  CT  II 5  0 
1/3 GG  CC  ID  7  4    
1/6 GC  CT  II  5  1    
2/3 GG  CT  ID  4  19    
2/4 GG  TT  ID  1  6    
3/5 GC  CC  ID  43  66     
3/6 GC  CT  ID  32  27     
3/8 GC  CT  DD  22  23     
4/6 GC  TT  ID  9  5    
5/5 CC  CC  DD  40  39     
7/8 CC  CT  DD  12  5    
8/8 CC  TT  DD  10  6    94
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increased serum VEGF levels (Shahbazi, 2002; 
Renner, 2000). Carriers of the 936 T allele have 
been shown to have lower VEGF plasma levels than 
non-carriers (Shahbazi, 2002; Renner, 2000). The 
936 C allele is one of the core sequences for the 
potential binding of Papillomavirus regulator E2 
and the C to T change at position 936 results in the 
loss of the core binding sequence for this transcrip-
tion factor. The third polymorphisms that we have 
studied is the −634 G   C that reported to was 
signiﬁ  cantly correlated with lipopolysaccharide 
(LPS)-stimulated VEGF production from periph-
eral blood mononuclear cells (PBMCs) of healthy 
subjects, also highest production was observed for 
the GG genotype, the intermediate production for 
the CG genotype, and lowest production for the CC 
genotype (Watson, 2000). On the contrary to Awata 
et al. who found signiﬁ  cantly higher VEGF levels 
in healthy subjects with the CC genotype than those 
with the other genotypes (Awata, 2002). In our 
study we didn’t ﬁ  nd any association between theses 
polymorphisms and asthma when we analyze each 
polymorphism independently. Therefore it would 
be helpful to have the plausibility of combining 
these three polymorphisms. The global test of 
haplotype association was statistically signiﬁ  cant 
(p   10
−3 ) and we suggest that −634C/+936T/ 
−2549D haplotype was associated with much 
higher risk of having asthma than other haplotypes.
The frequency of the T allele at the +936 C   T 
untranslated region of VEGF was (24.3%) in Tuni-
sian control population. This frequency was the 
highest compared with Italian population fre-
quency (19.4%), the American population (14%), 
and Korean population (13.4%) (Boiardi, 2003; 
Jacobs, 2006; Han, 2004). The frequency of the G 
allele at the -634 promoter region of VEGF gene 
in the present study is (50.4%) less than the 
frequencies found in American, Italian and Korean 
samples (68%, 61%, 57%) (Boiardi, 2003; Jacobs, 
2006; Han, 2004); which is more than frequency 
founded in Greek ethnicity (29.2%) (Papazoglou, 
2004), suggesting the ethnic variability in the 
allelic frequencies of this gene. Because of this 
variation in gene frequencies between different 
ethnic groups, it is of importance to note that it’s 
crucial to generalize these ﬁ  ndings when we try to 
establish the relationship between a polymorphic 
marker and asthma.
For the atopy part of this study, we did not ﬁ  nd 
a signiﬁ  cant statistically difference in the global 
distribution of genetic variants in spite the positive 
correlation found between VEGF and TH2 antigen 
sensitization (Lee, 2004) which imply that VEGF 
plays an important role in the development of atopy 
and subsequent atopic asthma.
A Major concern in case- control studies is the 
possibility of a false- positive association due to 
non homogeneity of the population structure. 
Indeed, one of the great advantages of family 
association study is the TDT which eliminates the 
possibility of spurious association due to popula-
tion heterogeneity. The Transmission disequilib-
rium test (TDT) is widely used as a robust 
statistical method to test for genetic association 
due to linkage based upon analysis of parent-
proband trios. However, Concerns about the 
potential of such designs to generate false posi-
tives as a result of poor matching between cases 
and controls has led to increasing use of family-
based association analysis and in particular, the 
transmission disequilibrium test (TDT) which 
overcomes this theoretical problem. But we fail 
to show any preferential transmission of alleles 
from parents to affected children and the TDT in 
the present study has not shown evidence for 
linkage between VEGF polymorphisms and 
asthma. This result can be explained by the 
inheritance of asthma and atopy which is likely 
to be complex and to be confounded by relatively 
small contributions from a number of different 
genes. It is also likely to be confounded by partial 
penetrance, by asymptomatic carriers who have 
not yet been exposed to the relevant environmen-
tal hazard and by disease phenocopies. All of 
these factors are likely to be operating, thereby 
decreasing the power of linkage analyses, which 
assume that asthma and atopy exhibits Mendelian 
inheritance.
Table 6. Results of the transmission disequilibrium test 
(TDT) for the VEGF polymorphisms.
Alleles Transmitted Non transmitted
−634 G 50 60
−634 C 60 50
+936 C 73 63
+936 T 63 73
−2549 I 64 78
18(bp)
−2549 D 78 64
18(bp) 96
Lachheb et al
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We acknowledge several limitations to our study. 
We only evaluated three functional polymorphisms 
of VEGF located in the same chromosome region 
6p21.3, in order to perform haplotype analysis. It is 
possible that other functional polymorphisms in the 
VEGF gene may affect the association between 
these polymorphisms and asthma risk. Needless to 
say, absence of an association between these speciﬁ  c 
polymorphisms of VEGF in case control and family 
study does not eliminate the importance of VEGF 
polymorphisms and their implication in the severity 
process of the disease. Although we demonstrated 
an association of +936 C   T with the severity of 
the disease, the investigation of −634 G   C poly-
morphism should not be discarded and further stud-
ies considering this genetic marker should be 
performed to evaluate its relevance in asthma.
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